Loading…
Chinese biopharma developing recombinant protein and antibody drugs; specific product line not fully established from available knowledge.
Chinese biopharma developing recombinant protein and antibody drugs; specific product line not fully established from available knowledge.
Moat: none
Headquarters: Beijing, China · Employees: 2,200
Size Sinocelltech (688520.SS) is a China Health Care company (Biotechnology) with a market value of $2.25B, the 1135th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥31.90 on 6 Nov 2026.
Performance Over six months the shares fell 22.5%, against +11.2% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 39.6% over the last twelve months (peer median +21.0%); the operating margin is -75.0% (peer median -3.9%).
Valuation It trades at 15.6× enterprise value to sales against a peer median of 5.5× (5th most expensive of 12).
Capital Return on invested capital runs 30.7 points below its cost of capital (8.7% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.14B | CN¥1.55B | CN¥2.50B | CN¥1.88B | CN¥1.02B |
| Revenue growth | — | -38% | +33% | +85% | — |
| Gross profit | CN¥1.05B | CN¥1.30B | CN¥2.25B | CN¥1.72B | CN¥924M |
| EBITDA | n/a | -CN¥259M | CN¥758M | CN¥164M | -CN¥239M |
| Net income | -CN¥958M | -CN¥565M | CN¥112M | -CN¥396M | -CN¥519M |
| Free cash flow | -CN¥555M | -CN¥490M | -CN¥248M | -CN¥886M | -CN¥976M |
| Capital expenditure | CN¥193M | CN¥217M | CN¥376M | CN¥505M | CN¥555M |
| Total debt | CN¥3.62B | CN¥3.90B | CN¥3.15B | CN¥2.75B | CN¥2.30B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688520.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.1% | +1.7% | 4th lowest of 21 |
| 6-month return | -22.5% | +11.2% | 2nd lowest of 21 |
| Distance from 52-week high | -43.0% | -27.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | -39.6% | +21.0% | 4th lowest of 14 |
| Operating margin | -75.0% | -3.9% | 4th lowest of 13 |
| EV / Sales | 15.6× | 5.5× | 5th most expensive of 12 |
| ROIC minus cost of capital | -30.7 pp | -6.4 pp | 4th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |